Glucagon-Like Peptide-1 Agonist Effects on Weight Loss and Heart Failure Hemodynamics.

Authors

Alberth Alvarado, John Martinez-Ponce, Oskar Ubysz, Anthony Costa, Lina Ataya, Daniel Brancheau

Published in

JACC. Case reports. Pages 110528. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

Optimization of fluid status in heart failure (HF) is challenging. The CardioMEMS system enables real-time pulmonary artery pressure monitoring, whereas glucagon-like peptide-1 (GLP-1) receptor agonists offer metabolic and potential hemodynamic benefits.
An 82-year-old man with HF (left ventricular ejection fraction: 40%-45%; NYHA functional class III) had recurrent decompensation despite diuretic agents. After CardioMEMS implantation, pressures remained elevated and variable. Initiation of semaglutide led to 20-pound weight loss, improved symptoms, and reduced mean pulmonary artery pressures (10 mm Hg).
This case highlights synergy between device-guided hemodynamic monitoring and GLP-1 therapy. Benefits include weight loss, improved congestion, and enhanced functional status, though caution is warranted in reduced-EF populations given mixed trial data.
Device-guided monitoring combined with GLP-1 therapy may enhance HF management. Further studies are needed to confirm safety, long-term outcomes, and applicability across diverse HF populations.
Combining CardioMEMS with GLP-1 therapy may improve HF management through tailored, data-driven care, but patient selection remains critical.

PMID:
42788915
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.